Results on FA pathway inactivation in pancreatic cancer cell lines have been previously reported and were confirmed, including defective FANCD2 monoubiquitination due to inactivating mutations in FANCG and FANCC in Hs766T and PL11 [20,22], respectively, and defective RAD51 focus formation due to an inactivating FANCD1 mutation in Capan-1 [17]. This evidence concerns the gene FANCG and pancreatic neoplasm.